Tinlarebant not checked
Belite Bio, Inc · LBS-008 · BPN-14967
FollowEvery change as it happens, and a Monday email
Trials
3 active
7 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Geographic Atrophy, STGD1, Stargardt Disease 1
- Main trialPhase 3
- “This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.”In the company’s words, NCT05949593 on ClinicalTrials.gov
- Other names
- LBS-008 · BPN-14967
Other drugs for Geographic Atrophy
- VonaprumentAnnexon, Inc. · Phase 3
- CemdisiranRegeneron · Phase 3
- PozelimabRegeneron · Phase 3
- BevemipretideMighty Therapeutics Inc. · Phase 2/3
- JNJ-81201887Johnson & Johnson (Janssen) · Phase 2/3
- BI 1584862Boehringer Ingelheim · Phase 2
Coming up2
- 30 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- Feb 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Jun 2027 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | |
| Phase 2/3Active, not recruiting | Feb 2028 | A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease | |
| Phase 3Completed | 4 Aug 2025 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease | |
| Phase 1/2Completed | 15 Aug 2023 | This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease | |
| Phase 1Completed | 20 Dec 2019 | Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults | |
| Phase 1Completed | 4 Jan 2023 | Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85 | |
| Phase 3Authorised | not given | An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026